Assenagon Asset Management S.A. Sells 79,071 Shares of Harrow, Inc. (NASDAQ:HROW)

Assenagon Asset Management S.A. cut its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 41.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 111,584 shares of the company’s stock after selling 79,071 shares during the quarter. Assenagon Asset Management S.A. owned 0.31% of Harrow worth $3,744,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. First Turn Management LLC acquired a new position in Harrow in the 3rd quarter valued at approximately $14,683,000. JPMorgan Chase & Co. grew its stake in shares of Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after purchasing an additional 194,480 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after purchasing an additional 166,602 shares during the period. Braidwell LP raised its position in Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company’s stock worth $19,766,000 after purchasing an additional 142,450 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Harrow during the 3rd quarter worth about $5,864,000. Institutional investors own 72.76% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on HROW. B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Lake Street Capital increased their price objective on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, Craig Hallum lifted their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, October 4th.

Harrow Price Performance

Shares of HROW opened at $36.10 on Wednesday. The firm has a market cap of $1.29 billion, a PE ratio of -38.40 and a beta of 0.72. Harrow, Inc. has a 52-week low of $9.13 and a 52-week high of $59.23. The business’s 50 day moving average price is $37.79 and its two-hundred day moving average price is $39.02. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.